Ide-Cel's Benefit on PF Survival: Doris Hansen, MD

Video

The hematologist from Moffitt Cancer Center discussed the survival benefit of ide-cel in the phase 2 KarMMa trial.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Doris Hansen, MD, assistant member, department of blood and marrow transplant and cellular immunotherapy. Moffitt Cancer Center, about the progression-free survival (PFS) benefit yielded by idecabtagene vicleucel (ide-cel; Abecma).

The phase 2 KarMMa trial (NCT03361748) demonstrated an overall response rate of 73% in patients with pretreated relapsed/refractory multiple myeloma. Median PFS was 8.6 months in patients with R/R MM.

The study examined the safety and efficacy of ide-cel in this patient population and was pivotal because it provided a new novel therapy to those who otherwise have limited options, according to Hansen. Patients with relapsed/refractory multiple myeloma often have a median PFS of 2 to 3 months, according to Hansen. However, patients who receive a BCMA-targeted CAR T-cell therapy experience improved outcomes, Hansen continues.

For example, results from the KarMMa study showed that patients who achieved a deep response with ide-cel, or a complete remission or better, had a median PFS of approximately 22 months, and a duration of response of 21 months. These results held up with a longer follow-up, Hansen concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.